Migraine and Hearing Disorders Link Explored

A systemic disorder of multisensory sensitization, migraine is far more than a severe headache. New research clarifies its strong and often overlooked connection to hearing health, including tinnitus and hyperacusis. A review published in the *Journal of Neurology* synthesizes evidence that for 15% to 49% of migraine patients, auditory symptoms are a core part of their condition (PMID: 42371148).

Migraine’s Auditory Reach: From Epidemiology to Electrophysiology

The team led by Xu, Zhai, and Chen compiled epidemiological data showing auditory issues are not a rare side effect but a prevalent phenotype. Sensorineural hearing loss, tinnitus, and hyperacusis are common. Perhaps more telling, nearly two-thirds of migraine patients exhibit objective auditory electrophysiological abnormalities. These are changes in the brain’s electrical response to sound, detectable even when a standard hearing test appears normal. This suggests the auditory system is involved in migraine pathology at a fundamental, often subclinical level.

This connection is more than simple comorbidity. As explored in our article on Integrated Auditory Health, hearing is a whole-brain process. Migraine appears to disrupt this process from the inner ear to the cortex.

The Three-Axis Pathophysiology: A Peripheral-to-Central Cascade

The review proposes a clear model for how migraine leads to auditory dysfunction. The problem unfolds across three interacting biological axes.

Axis 1: Anatomical and Vascular Vulnerabilities

The first axis involves the inner ear’s delicate structures. Anatomical and hydrodynamic factors can make the cochlea susceptible to the microvascular changes of a migraine attack. This can lead to localized ischemia—a temporary lack of blood flow—and disrupt the precise chemical balance of inner ear fluids. The result is a fragile environment where sensory cells are easily damaged.

Axis 2: Local Neurochemical Imbalance

Building on that vulnerability, the second axis involves a chemical storm. The same neuropeptides and inflammatory signals that drive migraine pain, like calcitonin gene-related peptide (CGRP), also affect the inner ear. Glutamate excitotoxicity, where nerve cells are overstimulated to the point of damage, and activation of the local immune system further disrupt cochlear homeostasis. This creates a direct pathway for migraine biology to cause hearing symptoms.

Axis 3: Central Sensitization and Network Dysfunction

The third and perhaps most significant axis is in the brain. Migraine is characterized by central sensitization, a state where the nervous system becomes hyper-reactive. In the auditory system, this manifests as impaired efferent gating—the brain loses its ability to filter out irrelevant sounds. It also leads to thalamocortical dysrhythmia, where the rhythmic communication between the thalamus (the brain’s sensory relay) and the auditory cortex becomes disordered. This is a likely mechanism for the persistent phantom perception of sound in tinnitus and the overwhelming loudness of hyperacusis.

This central hypersensitivity shares features with other conditions. For instance, the neural network plasticity seen here has parallels with the mechanisms discussed in PTSD and Tinnitus: Shared Symptoms and Neurobiology. Furthermore, chronic central arousal can worsen sleep, which is critical for neural recovery; research on SleepScience.space shows how baseline states like depression can influence long-term treatment outcomes for sleep disorders, a consideration relevant for managing migraine-related auditory issues.

From Mechanism to Management: A New Therapeutic Framework

The authors argue that current clinical management is often fragmented. By understanding these three axes, treatment can become more targeted and cross-disciplinary. They categorize strategies by specific clinical objectives.

The first objective is blocking upstream migraine pathways. This includes established and new migraine medications, such as CGRP inhibitors, which may calm the systemic neurochemical disturbance before it affects the ear.

The second is protecting the cochlear microenvironment. This could involve exploring otoprotective agents—drugs that shield sensory cells—during migraine episodes, especially for patients with fluctuating hearing loss.

The third objective is correcting central hypersensitivity. This is where sound therapy, cognitive behavioral therapy (CBT), and neuromodulation techniques come in. Approaches that retrain the brain’s auditory processing, such as those used for managing misophonia, could be adapted. Techniques like vagus nerve stimulation, which we cover in our article on Vagus Nerve Stimulation for Tinnitus Relief, aim directly at stabilizing hyperactive neural networks.

Implications for Patients and Clinicians

This research has direct practical implications. For patients with migraine, unexplained hearing symptoms like ringing, fullness, or sound sensitivity should be discussed with their neurologist and an audiologist. Comprehensive assessment should go beyond a standard audiogram to include tests of auditory processing and electrophysiology.

For clinicians, the message is to integrate care. An ENT or audiologist seeing a patient with hyperacusis should screen for migraine history. A neurologist managing migraine should ask about auditory symptoms. Early identification and precise phenotyping are the first steps toward using the framework proposed by Xu, Zhai, Chen, and their colleagues. Their work moves the conversation past simple association and provides a roadmap for treating the auditory system as an integral part of the migraine disorder.